This randomized controlled trial compared outcomes of 110 patients with polycystic ovary syndrome (PCOS) undergoing in vitro fertilization (IVF) using a flexible gonadotropin-releasing hormone (GnRH) antagonist protocol versus 110 patients using a long GnRH agonist down-regulation protocol. The study found no difference in ongoing pregnancy rates between the two groups. However, the incidence of moderate ovarian hyperstimulation syndrome (OHSS) was lower and stimulation time and gonadotropin dosage required were both lower in the antagonist group compared to the agonist group. The study concluded that for PCOS patients undergoing IVF, the flexible GnRH antagonist protocol results in similar ongoing pregnancy rates but lower risk
Pregnancy outcome following swim up preparation of both fresh and cryopreserv...lukeman Joseph Ade shittu
This study was designed to assess the impact of swim up preparation of both fresh and cryopreserved sperm on the pregnancy outcome in a private fertility centre in Lagos. A cross-sectional prospective analysis of 34 asthenozoospermic semen samples of men whose wives were undergoing assisted reproduction was studied. The basic semen parameters comprising of the volume, count, and motility of the sperm before and after swim up preparations with pregnancy outcome were measured. For fresh semen (n = 28, mean age = 37.0 ± 1.1 years, mean volume = 2.16 ± 0.1 ml), the sperm count decreased significantly (p<0.01)><0.01)><0.01)><0.01) from 25.1 ± 4.01 to 32.8 ± 6.18%. The pregnancy outcome of cryopreserved was 30%. The pregnancy outcome was higher with fresh than the cryopreserved semen. However, the motility was a significant indicator for the successful outcome. Swim up procedure improve the motility of both cryopreserved and fresh semen with a better pregnancy outcome in this study.
Elonva is a new drug for ovarian stimulation in IVF that has to be studied through randomised controlled trials. Moreover, Meta-analysis of RCTs would enable clinicians and researchers to identify potential benefits and risks
Anti-Müllerian Hormone (AMH) is critical for physiologic involution of the Mullerian ducts during sexual differentiation in the male foetus.
In women,AMH is a product of the small antral follicles in the ovaries and serves to function as an autocrine and paracrine regulator of follicular maturation
Pregnancy outcome following swim up preparation of both fresh and cryopreserv...lukeman Joseph Ade shittu
This study was designed to assess the impact of swim up preparation of both fresh and cryopreserved sperm on the pregnancy outcome in a private fertility centre in Lagos. A cross-sectional prospective analysis of 34 asthenozoospermic semen samples of men whose wives were undergoing assisted reproduction was studied. The basic semen parameters comprising of the volume, count, and motility of the sperm before and after swim up preparations with pregnancy outcome were measured. For fresh semen (n = 28, mean age = 37.0 ± 1.1 years, mean volume = 2.16 ± 0.1 ml), the sperm count decreased significantly (p<0.01)><0.01)><0.01)><0.01) from 25.1 ± 4.01 to 32.8 ± 6.18%. The pregnancy outcome of cryopreserved was 30%. The pregnancy outcome was higher with fresh than the cryopreserved semen. However, the motility was a significant indicator for the successful outcome. Swim up procedure improve the motility of both cryopreserved and fresh semen with a better pregnancy outcome in this study.
Elonva is a new drug for ovarian stimulation in IVF that has to be studied through randomised controlled trials. Moreover, Meta-analysis of RCTs would enable clinicians and researchers to identify potential benefits and risks
Anti-Müllerian Hormone (AMH) is critical for physiologic involution of the Mullerian ducts during sexual differentiation in the male foetus.
In women,AMH is a product of the small antral follicles in the ovaries and serves to function as an autocrine and paracrine regulator of follicular maturation
The purpose of this study was to investigate any
influence of maternal and/or paternal age, three sperm
parameters (sperm count/ml, motility and morphology) on
pregnancy outcomes in intracytoplasmic sperm injection (ICSI)
cycles. In all, 785 ICSI cases were analyzed retrospectively.
Pregnancy outcome were influenced by the age of the maternal,
paternal partners and sperm count x10⁶. The clinical pregnancy
rate with respect to the age of female partner and male partner
was revealed a significant inverse correlation between them with
(P = <0.001) for each partner. The relationship between clinical
pregnancy rate and sperm count x10⁶/ml was revealed a
significant difference between the groups (P= 0.046). On the other
hand no basic semen parameters (motility and normal
morphology) influence on ICSI pregnancy outcome was found in
the subgroup of patients. We conclude that the influence on
pregnancy outcome after ICSI is related mostly to maternal and
paternal age.
Study design: A Randomized prospective comparable study.
Objective: To compare the effi cacy of GnRH agonist stop antagonist and GnRH antagonist protocols in ICSI outcome for women
who are expected to have poor ovarian response.
Setting: ART unit of Obstetrics and Gynecology Department of Qena University Hospital, South Valley University, Egypt.
Duration: From September 2016 to December 2017.
Intrauterine insemination (IUI) is procedure which involves placing sperm inside a woman's uterus to facilitate fertilization. The ovaries are stimulated with tablets and injections and then monitored for the probable time of ovulation. For more info visit :-//www.newhopeivf.com/intrauterine-insemination-iui.html
Live birth by fallopian tube sperm perfusion in hyperprolactinemic woman afte...lukeman Joseph Ade shittu
The case presented describes a live birth following treatment of a 35-year-old woman with fallopian tube sperm perfusion (FTSP) using donor sperm after three-repeated unsuccessful courses of In-vitro fertilization (IVF) with Percutaneous Epididymal Sperm Aspiration (PESA), Testicular Sperm Extraction (TESE), and donor sperm. The indication of FTSP is hereby explored and discussed.
Intrauterine insemination versus fallopian tube sperm perfusion in non tubal ...Internet Medical Journal
Background: Controlled ovarian hyper stimulation (COH) combined with intrauterine insemination (IUI), using a volume of 0.5 mail of inseminate is commonly offered to couples with non tubal infertility. Another method is Fallopian tube sperm perfusion (FSP) which is based on a pressure injection of 4 ml of sperm suspension while attempting to seal the cervix to prevent semen reflux. This technique ensures the presence of higher sperm density in the fallopian tubes at the time of ovulation than standard IUI. The aim of this study was to compare the efficiency of IUI and FSP in the treatment of infertility.
Methods: 200 consecutive patients with infertility in 404 stimulated cycles were included in the study. Those randomized to standard IUI included 100 patients in 184 cycles [158 Clomiphene citrate/human menopausal gonadotrophin cycles and 26 Letrozole/FSH cycles exclusively for polycystic ovarian disease patients] (group A). Patients subjected to FSP included 100 patients in 220 cycles (193 Clomiphene citrate/human menopausal gonadotrophin cycles and 27 Letrozole/FSH cycles exclusively for polycystic ovarian disease patients] (group B). Swim up semen preparation technique was used in all cases. Insemination was performed in both groups 34-37 hours after hCG administration. Standard IUI was performed using 0.5 ml of inseminate. In FSP 4ml inseminate was used.
Results: In group A (184 IUI cycles in 100 patients), 22 clinical pregnancies (presence of gestational sac with fetal cardiac activity) occurred (11.95% per cycle over four cycles). In group B, (220 cycles of FSP in 100 patients), 48 clinical pregnancies occurred (21.81%per cycle over four cycles) and this difference was statistically significant (p<0.05).
Conclusions: For non-tubal sub fertility, the results indicate clear benefit for FSP (Fallopian tube sperm perfusion) over IUI (Intrauterine insemination).
Key Words: Intrauterine insemination, Fallopian tube sperm perfusion, Non-tubal infertility.
Authors: Dr. Col (Retd) G S Shekhawat, MD(Obst & Gyn) * (Corresponding. Author), Dr Priyanka S, MBBS+
The purpose of this study was to investigate any
influence of maternal and/or paternal age, three sperm
parameters (sperm count/ml, motility and morphology) on
pregnancy outcomes in intracytoplasmic sperm injection (ICSI)
cycles. In all, 785 ICSI cases were analyzed retrospectively.
Pregnancy outcome were influenced by the age of the maternal,
paternal partners and sperm count x10⁶. The clinical pregnancy
rate with respect to the age of female partner and male partner
was revealed a significant inverse correlation between them with
(P = <0.001) for each partner. The relationship between clinical
pregnancy rate and sperm count x10⁶/ml was revealed a
significant difference between the groups (P= 0.046). On the other
hand no basic semen parameters (motility and normal
morphology) influence on ICSI pregnancy outcome was found in
the subgroup of patients. We conclude that the influence on
pregnancy outcome after ICSI is related mostly to maternal and
paternal age.
Study design: A Randomized prospective comparable study.
Objective: To compare the effi cacy of GnRH agonist stop antagonist and GnRH antagonist protocols in ICSI outcome for women
who are expected to have poor ovarian response.
Setting: ART unit of Obstetrics and Gynecology Department of Qena University Hospital, South Valley University, Egypt.
Duration: From September 2016 to December 2017.
Intrauterine insemination (IUI) is procedure which involves placing sperm inside a woman's uterus to facilitate fertilization. The ovaries are stimulated with tablets and injections and then monitored for the probable time of ovulation. For more info visit :-//www.newhopeivf.com/intrauterine-insemination-iui.html
Live birth by fallopian tube sperm perfusion in hyperprolactinemic woman afte...lukeman Joseph Ade shittu
The case presented describes a live birth following treatment of a 35-year-old woman with fallopian tube sperm perfusion (FTSP) using donor sperm after three-repeated unsuccessful courses of In-vitro fertilization (IVF) with Percutaneous Epididymal Sperm Aspiration (PESA), Testicular Sperm Extraction (TESE), and donor sperm. The indication of FTSP is hereby explored and discussed.
Intrauterine insemination versus fallopian tube sperm perfusion in non tubal ...Internet Medical Journal
Background: Controlled ovarian hyper stimulation (COH) combined with intrauterine insemination (IUI), using a volume of 0.5 mail of inseminate is commonly offered to couples with non tubal infertility. Another method is Fallopian tube sperm perfusion (FSP) which is based on a pressure injection of 4 ml of sperm suspension while attempting to seal the cervix to prevent semen reflux. This technique ensures the presence of higher sperm density in the fallopian tubes at the time of ovulation than standard IUI. The aim of this study was to compare the efficiency of IUI and FSP in the treatment of infertility.
Methods: 200 consecutive patients with infertility in 404 stimulated cycles were included in the study. Those randomized to standard IUI included 100 patients in 184 cycles [158 Clomiphene citrate/human menopausal gonadotrophin cycles and 26 Letrozole/FSH cycles exclusively for polycystic ovarian disease patients] (group A). Patients subjected to FSP included 100 patients in 220 cycles (193 Clomiphene citrate/human menopausal gonadotrophin cycles and 27 Letrozole/FSH cycles exclusively for polycystic ovarian disease patients] (group B). Swim up semen preparation technique was used in all cases. Insemination was performed in both groups 34-37 hours after hCG administration. Standard IUI was performed using 0.5 ml of inseminate. In FSP 4ml inseminate was used.
Results: In group A (184 IUI cycles in 100 patients), 22 clinical pregnancies (presence of gestational sac with fetal cardiac activity) occurred (11.95% per cycle over four cycles). In group B, (220 cycles of FSP in 100 patients), 48 clinical pregnancies occurred (21.81%per cycle over four cycles) and this difference was statistically significant (p<0.05).
Conclusions: For non-tubal sub fertility, the results indicate clear benefit for FSP (Fallopian tube sperm perfusion) over IUI (Intrauterine insemination).
Key Words: Intrauterine insemination, Fallopian tube sperm perfusion, Non-tubal infertility.
Authors: Dr. Col (Retd) G S Shekhawat, MD(Obst & Gyn) * (Corresponding. Author), Dr Priyanka S, MBBS+
Which type of Gonadotrophins should we use for ovarian stimulation in IVF?Hesham Al-Inany
There are many types of gonadotropins: some are recombinant , others are urinary derived. some contain LH like activity , others do not. which to use?? many research with conflicting results but the final word came from Cochrane mega- systematic review. This talk will illustrate this issue
recurrent miscarriage is a real clinical problem with different aetioogies. However, recent observations pointed to vascular dysfunction as a main underlying factor: how ? this talk may help in illustrating this
Antagonist - Tips and tricks to optimize use in Intra Uterine Insemination (I...Anu Test Tube Baby Centre
Presentation given in 2017. Management of infertility using assisted reproductive technologies.
What is the role of antagonist in IUI and IVF - tips and tricks to optimize its use.
Strategies for Improving Success Rates in ART PARTLifecare Centre
Strategies for Improving Success Rates in ART
Part - 2
Strategies for Improving Success Rates in ART
Tailoring Controlled Ovarian Stimulation
Strategies for Luteal Phase in ART cycles
Endometrial Receptivity Array
Adjuvant therapy, also known as adjunct therapy or add-on therapy, is therapy given in addition to the primary or initial therapy to maximize its effectiveness.
Add-ons have become ubiquitous with the process of assisted reproduction (ART) which is markedly more complex than it was at its inception.
How to prevent occurrence of severe ovarian hyperstimulation in IVF. Is there a way ? this talk will present a pilot randomised study that may shed the light on this
Similar to Flexible gn rh antagonist protocol.full (20)
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
1. Human Reproduction, Vol.25, No.3 pp. 683–689, 2010
Advanced Access publication on December 15, 2009 doi:10.1093/humrep/dep436
ORIGINAL ARTICLE Infertility
Trifon G. Lainas 1, Ioannis A. Sfontouris 1, Ioannis Z. Zorzovilis 1,
George K. Petsas 1, George T. Lainas 1, Efthymia Alexopoulou 2,
and Efstratios M. Kolibianakis 3,4
1
Eugonia-Iatriki Erevna IVF Center, Athens, Greece 22nd Department of Radiology, Medical School, University of Athens, Attikon University
Hospital, Athens, Greece 3Unit for Human Reproduction, Aristotle University of Thessaloniki, Skoufa 5 Str, Pilea, Thessaloniki 55535, Greece
4
Correspondence address. Fax: þ30-2310-821420; E-mail: stratis.kolibianakis@gmail.com
background: Women with polycystic ovary syndrome (PCOS) are at risk of developing ovarian hyperstimulation syndrome (OHSS)
during ovarian stimulation. Use of GnRH antagonist in the general subfertile population is associated with lower incidence of OHSS than
agonists and similar probability of live birth but it is unclear if this is true for patients with PCOS. Our aim was to compare the flexible
GnRH antagonist and GnRH agonist long protocols in patients with PCOS undergoing IVF (primary end-point: ongoing pregnancy rate
per patient randomized).
methods: In this randomised controlled trial (RCT), 220 patients with PCOS were randomly allocated in two groups: long GnRH agonist
down-regulation protocol (n ¼ 110) and flexible GnRH antagonist protocol (n ¼ 110).
results: No differences were observed in ongoing pregnancy rates [50.9 versus 47.3%, difference 3.6%, 95% confidence interval (CI):
29.6 to þ16.8%] in the agonist and antagonist protocols, respectively. Incidence of OHSS Grade II was lower in the antagonist compared
with agonist group (40.0 versus 60.0%, difference 220.0%, 95% CI: 27.1 to 232.9%, P , 0.01). Duration of stimulation (10 versus 12 days,
difference 2 days, 95% CI: þ1 to þ2, P , 0.001) and total gonadotrophin required (1575 versus 1850 IU, difference 2275 IU, 95% CI: 225
to 2400, P , 0.05) were also lower in the antagonist compared with agonist protocol.
conclusions: The current RCT suggests that the flexible GnRH antagonist protocol is associated with a similar ongoing pregnancy
rate, lower incidence of OHSS grade II, lower gonadotrophin requirement and shorter duration of stimulation, compared with GnRH
agonist. The GnRH antagonist might be the treatment choice for patients with PCOS undergoing IVF.
The study was registered at clinicaltrials.gov. ID: NCT00417144.
Key words: GnRH antagonists / GnRH agonists / polycystic ovary syndrome / ovarian hyperstimulation syndrome / pregnancy rates
Introduction
Polycystic ovary syndrome (PCOS) is a common endocrinopathy that
affects 5– 10% of women of reproductive age. Despite the development of universally accepted criteria for the diagnosis of the syndrome
by the European Society for Human Reproduction (ESHRE) and the
American Society of Reproductive Medicine (ASRM) (The Rotterdam
ESHRE/ASRM-sponsored PCOS consensus workshop group, 2004),
the optimal infertility treatment for PCOS women is still a matter of
controversy. Recently, a consensus was reached on treatment for
PCOS patients, that includes the use of clomiphene citrate, exogenous
gonadotrophins, laparoscopic ovarian surgery and IVF (The
& The Author 2009. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved.
For Permissions, please email: journals.permissions@oxfordjournals.org
Downloaded from http://humrep.oxfordjournals.org/ at Merck and Co Inc on October 11, 2013
Downloaded from http://humrep.oxfordjournals.org/ at Merck and Co Inc on October 11, 2013
Downloaded from http://humrep.oxfordjournals.org/ at Merck and Co Inc on October 11, 2013
Downloaded from http://humrep.oxfordjournals.org/ at Merck and Co Inc on October 11, 2013
Downloaded from http://humrep.oxfordjournals.org/ at Merck and Co Inc on October 11, 2013
Downloaded from http://humrep.oxfordjournals.org/ at Merck and Co Inc on October 11, 2013
Downloaded from http://humrep.oxfordjournals.org/ at Merck and Co Inc on October 11, 2013
Flexible GnRH antagonist protocol
versus GnRH agonist long protocol
in patients with polycystic ovary
syndrome treated for IVF: a
prospective randomised controlled
trial (RCT)
2. 684
Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop
Group, 2008).
PCOS patients undergoing IVF have a high risk of developing ovarian
hyperstimulation syndrome (OHSS) (Delvigne et al., 1993), a serious
iatrogenic complication of ovarian stimulation, triggered by exogenous
and/or endogenous hCG. The introduction of GnRH antagonists in
recent years, with a now established decrease in the incidence of
OHSS as compared with GnRH agonists in the general population
(Kolibianakis et al., 2006; Aboulghar et al., 2007), might offer a new
safer treatment option for these patients.
However, in PCOS patients very few studies have been published
comparing agonist and antagonist protocols (Hohmann et al., 2003;
Hwang et al., 2004; Bahceci et al., 2005; Ragni et al., 2005; Lainas
et al., 2007). As a result, available data so far cannot lead to reliable
conclusions (Griesinger et al., 2006).
The aim of the present RCT was to compare the flexible GnRH
antagonist and the GnRH agonist long protocols in a large group of
PCOS patients undergoing IVF treatment, with primary end-point
being ongoing pregnancy rate per patient randomized.
Materials and Methods
Patient population and study design
This is a single center RCT performed at the Eugonia-Iatriki Erevna IVF unit
from November 2004 to February 2008. Random allocation was performed by a study nurse at consultation, using a computer generated randomization list, in a 1:1 ratio. Patients were treated either by a long GnRH
agonist down regulation protocol (n ¼ 110, agonist group) or by a flexible
GnRH antagonist protocol (n ¼ 110, antagonist group). Neither patients
nor doctors were blinded to the treatment assigned. The study was
approved by our institutional ethics review board. An informed consent
was obtained from all patients included in this study.
Patients could enter the study only once after being diagnosed as PCOS
[presence of oligoovulation/anovulation (Ehrmann et al., 2006) and polycystic ovaries]. Additional inclusion criteria were: age 18 – 39 years, no
endometriotic cyst present, as assessed by transvaginal ultrasound examination, and basal hormonal levels of FSH in the early follicular phase
of 10 IU/ml. Patients with known previous poor ovarian response
(Kolibianakis et al., 2004) were excluded.
Ovarian stimulation
All patients received oral contraceptive pill (OCP) starting on Day 2 of
spontaneous menses of the cycle prior to the treatment cycle, after
blood test confirmed the presence of a baseline hormone profile. The
OCP contained 0.03 mg ethinyl estradiol (E2) and 0.075 mg gestodene
(Minulet, Wyeth, Greece). OCPs were taken daily for 21 days.
Patients in the agonist group were administered s.c. GnRH agonist
0.1 mg triptorelin (Arvekap, Ipsen, France) daily. The agonist was
started 3 days before discontinuation of the OCP. All patients had
blood loss after discontinuation of the OCP. When desensitization was
achieved (10 – 15 days after the initiation of GnRH agonists), as evidenced by plasma E2 levels of 50 pg/ml, the absence of ovarian follicles
and endometrial thickness 6 mm on transvaginal ultrasound examination
(Barash et al., 1998), daily s.c. injection of recombinant FSH (rFSH,
Puregon, Organon, The Netherlands) was commenced. The dose of
GnRH agonist was decreased on that day to 0.05 mg/day and continued
until and including the day of triggering of final oocyte maturation.
In the flexible GnRH antagonist protocol (antagonist group) daily s.c
administration of ganirelix 0.25 mg (Orgalutran, Organon, The
Lainas et al.
Netherlands) was initiated when at least one of the following criteria
were fulfilled: (i) the presence of at least one follicle measuring
.14 mm; (ii) serum E2 levels .600 pg/ml; and (iii) serum LH levels
.10 IU/l (Lainas et al., 2005).
In the antagonist protocol patients started daily rFSH treatment with s.c
injections of follitropin b (Puregon, Organon, The Netherlands), on Day 2
of cycle that followed the discontinuation of the OCP. Treatment with
rFSH and GnRH antagonist continued daily thereafter, until and including
the day of triggering of final oocyte maturation.
The starting dose of rFSH was 150 IU/day for all patients in both
groups. This dose was adjusted after Day 5 of stimulation, depending on
the ovarian response, as assessed by E2 levels and ultrasound. As soon
as three follicles reached a mean diameter of 17 mm, 5000 IU of hCG
(Kolibianakis et al., 2007b) (Pregnyl, Organon, The Netherlands) were
administered i.m.
Oocyte retrieval, embryo transfer, luteal
support
Oocyte retrieval was performed 35– 36 h after the hCG injection by transvaginal ultrasound-guided double lumen needle aspiration. ICSI was performed only in cases with severe male factor or previous fertilization
failure. Ultrasound guidance was used for all embryo transfers, which
were performed 2 or 3 days post-oocyte retrieval, depending on the
weekly clinical program (i.e. to avoid embryo transfer on Sundays). Day
2 and Day 3 embryo transfers were equally distributed in the two
groups. Luteal phase support with 600 mg of micronized progesterone
(Utrogestan Laboratoires Besins-International S.A., France) was initiated
2 days after oocyte retrieval.
Embryo transfer was cancelled and elective embryo cryopreservation
was performed in cases of early OHSS, detected 3 days post-oocyte
retrieval, that could possibly lead to life-threatening OHSS (Navot et al.,
1992), or in cases fulfilling one or more of the criteria for hospitalization
(The Practice Committee of the American Society for Reproductive
Medicine, 2004), described below in grade III OHSS.
Classification of OHSS
A modified classification system based on combined criteria previously
reported (Golan et al., 1989; Navot et al., 1992; Rizk and Aboulghar,
1999) was used in the current study.
Grade I included patients with no or mild manifestations of OHSS who
did not need any treatment or monitoring as a result of ovarian
hyperstimulation.
Grade II included patients who were not hospitalized as a result of
OHSS and required monitoring on an outpatient basis. These patients
had either (a) moderate OHSS, with discomfort, abdominal pain,
nausea, distension, ultrasonic evidence of ascites, haematocrit (Ht) ,
45%, white blood cells (WBC) , 15 000 (Golan et al., 1989; Navot
et al., 1992; Rizk and Aboulghar, 1999) and enlarged ovaries (maximum
diameter ,10 cm), requiring frequent monitoring, or (b) severe OHSS
requiring daily monitoring, with Ht . 45%, WBC . 15 000, nausea,
abdominal pain, clinical evidence of ascites, marked distension of the
abdomen, marked ascites (Golan et al., 1989; Navot et al., 1992; Rizk
and Aboulghar, 1999) and ultrasound showing large ovaries (maximum
diameter .10 cm).
Grade III OHSS included women who were hospitalized either because
they developed critical OHSS (Navot et al., 1992) (i.e. Ht . 55, WBC .
25 000 and creatinine .1.5), or because they fulfilled one or more of the
criteria for hospitalization described by the Practice Committee of the
ASRM (2004). These criteria include severe abdominal pain or peritoneal
signs, intractable nausea and vomiting, severe oliguria or anuria, tense
ascites, dyspnea or tachypnea, hypotension, dizziness or syncope, severe
3. 685
GnRH antagonist or agonist in polycystic ovary syndrome
electrolyte imbalance, haemoconcentration and abnormal liver function
tests (The Practice Committee of the American Society for Reproductive
Medicine, 2004).
Ultrasound and laboratory assays
All ultrasound measurements were performed using a 7.5 or 6 or 5 MHz
vaginal probe (Sonoline Adara, Siemens). FSH, LH, E2 and progesterone
levels were measured using an Immulite analyzer and commercially available kits (DPC, Los Angeles, CA, USA). Analytical sensitivity were
0.1 mIU/ml for FSH, 0.1 mIU/ml for LH, 15 pg/ml for E2 and 0.2 ng/ml
for progesterone. Intra- and inter-assay precision at the concentrations
of most relevance to the current study (expressed as coefficients of variation) were 2.6 and 5.8% for FSH, 5.9 and 8.1% for LH, 6.3 and 6.4% for
E2 and 7.9 and 10% for progesterone, respectively.
Outcome measures
The primary outcome measure was ongoing pregnancy rate per patient
randomized. Ongoing pregnancy and clinical pregnancy were defined as
the presence of gestational sac with fetal heart beat detection at 12
weeks and at 6 – 7 weeks of gestation, respectively.
Secondary outcome measures were incidence of OHSS, duration of
rFSH stimulation, total dose of rFSH, E2 and progesterone concentration
on the day of hCG administration, cycle cancellation rate, number of
cumulus-oocyte complexes (COCs) retrieved, number of metaphase II
oocytes and fertilization rates.
Power analysis
We selected to set the baseline ongoing pregnancy rate for PCOS patients
at 35%, and the detectable difference between groups at 5%, assuming an
alpha level of 0.05. It was calculated that a sample size of 1471 patients
was required in each group to achieve a 0.80 power. In confirmation of
the values used for power analysis, Griesinger et al. (2006) reported
41.6 and 37.1% clinical pregnancy rates in PCOS patients treated by
agonist and antagonist protocols respectively. In addition, Heijnen et al.
(2006) showed that PCOS and control IVF patients achieve similar clinical
pregnancy rates of approximately 35%, a percentage that was also
accepted by The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus
Workshop Group (2008).
Obtaining such a sample size (1471 patients per group) is not easy to
achieve in a single center, and is also extremely difficult for multicenter
studies, especially when it refers to a small proportion of the population,
such as PCOS patients, even during a 4-year period. Even for a 20% baseline pregnancy rate with 5% difference, more than 900 patients per group
would be required. In addition, detecting a difference of 10% in pregnancy
rates, which is not supported by the data published so far, would still
require a considerable number of patients in each group (n ¼ 376).
Despite this, however, we decided to embark on this trial with the aim
to produce, to the best of our knowledge, the largest comparative trial to
date of GnRH analogues in PCOS patients that could be incorporated in a
future meta-analysis.
Results
Statistical analysis
Proportions were compared with the Fisher’s exact test or the x2 test,
where appropriate. Continuous variables (age, BMI), were compared
with the Student’s t-test for independent samples or the Mann –
Whitney depending on the normality of their distribution. Statistical significance was accepted when P 0.05.
Baseline characteristics and hormonal profile of the patients analyzed
are shown in Table I, although Table II shows ovarian stimulation
characteristics and hormonal data on the day of hCG administration.
No significant differences were observed between the agonist and the
antagonist group regarding baseline characteristics and hormonal profile.
Table I Baseline characteristics and hormonal profile of patients with PCOS in the GnRH agonist and GnRH antagonist
group
Agonist group (n 5 110)
Antagonist group (n 5 110)
.............................................................................................................................................................................................
Baseline characteristics
Age (years)
BMI (kg/m2)
32 (29– 35)
23.2 (20.9– 25.8)
31 (28 –35)
24.6 (20.9 –29.3)
Duration of infertility (years)
3 (2–5)
3 (2– 5)
Number of previous IVF attempts
1 (0–4)
1 (0– 3)
Subjects with previous IVF attempts, n (%)
69 (62.7, 53.7–71.7)
69 (62.7, 53.7– 71.7)
PCOS only
22 (20.0, 12.5–27.5)
28 (25.5, 17.3– 33.6)
PCOS þ male factor
53 (48.2, 38.9–57.5)
52 (47.3, 38.0– 56.6)
PCOS þ tubal factor
27 (24.5, 16.5–32.5)
18 (16.4, 9.5–23.3)
8 (7.3, 2.4– 12.2)
12 (10.9, 5.1–6.7)
Indication for IVF, n (%, 95% CI)
PCOS þ other
Baseline hormonal profile
FSH (IU/l)
6.0 (4.3–6.9)
6.2 (4.8– 7.5)
LH (IU/l)
5.9 (3.4–7.6)
5.3 (4.0– 7.5)
E2 (pg/ml)
30 (19– 44)
Progesterone (ng/ml)
0.57 (0.45– 0.78)
Values are expressed as medians (lower-upper quartiles) unless stated otherwise. Differences between groups are not statistically significant.
E2, estradiol; CI, confidence interval.
30 (19 –43)
0.54 (0.40 –0.74)
4. 686
Lainas et al.
Table II Ovarian stimulation characteristics and hormonal data on the day of hCG in the GnRH agonist and antagonist
group
Agonist group (n 5 110)
Antagonist group (n 5 110)
P-value
.............................................................................................................................................................................................
Stimulation period (days)
12 (10– 12)
Total FSH (IU)
10 (9–11)
1850 (1370– 2480)
0.001
1575 (1306–2212)
0.019
Number of oocytes retrieved
27 (20– 33)
28 (20–36)
0.289
Mature oocytes (in ICSI patients)
18 (11– 25)
21 (10–26)
0.604
IVF
58 (52.7, 43.4– 62.0)
52 (47.3, 38.0–56.6)
0.578
ICSI
38 (34.5, 25.6– 43.4)
39 (35.5, 26.6–44.4)
Type of fertilization, n (%, 95% CI)
IVF þ ICSI
14 (12.7, 6.5 –18.9)
Fertilization rate (%)
19 (17.3, 10.2–24.4)
53.3 (40.6 –68.5
55.0 (38.9–66.7)
0.795
Within IVF
62.2 (47.7 –74.7)
64.0 (50.0–71.1)
0.959
Within ICSI
45.5 (41.2 –56.5)
46.9 (34.4–57.1)
0.962
Within ICSI þ IVF
42.0 (32.1 –56.6)
E2 concentration on hCG day (pg/ml)
PRG concentration on hCG day (ng/ml)
Number of embryos transferred
44.8 (38.4–60.5)
0.414
2850 (1994– 3585)
2144 (1533–2977)
0.004
1.1 (0.7– 1.4)
1.1 (0.9–1.4)
Embryo transfer day (Day 3/Day 2)
Cycle/embryo transfer cancellations
75/35
0.185
3 (2–3.5)
3 (2– 4)
0.297
72/38
5 (4.5%)
0.668
4 (3.6%)
0.734
Statistical differences were calculated using the non-parametric Mann –Whitney test, except for ‘type of fertilization’ where the x2 test was used.
Values are expressed as medians (lower-upper quartiles) unless stated otherwise. P-values in bold indicate statistical significance.
PRG, progesterone.
Table III Achievement of pregnancy in the GnRH agonist and antagonist groups
Agonist group (n 5 110)
Antagonist group (n 5 110)
Difference % (95% CI)
P (Fisher’s exact test)
.............................................................................................................................................................................................
Biochemical pregnancy, % (n)
68.2 (75)
62.7 (69)
5.5 (27.0 to þ17.9)
0.479
Clinical pregnancy, % (n)
61.8 (68)
52.7 (58)
9.1 (23.9 to þ22.0)
0.220
Ongoing pregnancy, % (n)
50.9 (56)
47.3 (52)
3.6 (29.6 to þ16.8%)
0.686
The antagonist group was characterized by a shorter stimulation
period [10 versus 12 days, difference 2 days, 95% confidence interval
(CI): þ1 to þ2, P , 0.001], a reduced amount of total gonadotrophin
units required (1575 versus 1850 IU, difference 2275 IU, 95% CI:
225 to 2400, P , 0.05) and a lower E2 concentration on the day
of hCG administration (2144 versus 2850 pg/ml; difference
2706 pg/ml, 95% CI: 2240 to 2841; P , 0.01).
No significant differences were observed in ongoing pregnancy rates
[50.9% (56/110) versus 47.3% (52/110)], as well as in biochemical
[68.2% (75/110) versus 62.7% (69/110)], and clinical pregnancy
rates [61.8% (68/110) versus 52.7% (58/110)] between the agonist
and the antagonist group, respectively (Table III). Logistic regression
with the dependent variable ongoing pregnancy, and independent variables the baseline characteristics of patients recruited and type of
stimulation protocol, revealed a significant negative (adverse) effect
of the number of previous attempts and BMI on the outcome
(Table IV).
A significantly higher proportion of women (55.5 versus 34.5%, P ,
0.001) in the antagonist as compared with the agonist group
developed Grade I OHSS (Table V). Conversely, a significantly
greater proportion of women developed grade II OHSS in the
agonist group (60.0 versus 40.0%, P , 0.01).
All patients proceeded at least to oocyte retrieval. Cycle cancellations were therefore equivalent to cancellations of embryo transfer
and elective cryopreservation of all embryos. Cycle/embryo transfer
cancellations were similar in the agonist and antagonist protocol
[five patients (4.5%) versus four patients (3.6%); Table II].
Discussion
The present study evaluated the comparative efficacy of the flexible
GnRH antagonist and the long GnRH agonist down-regulation protocol in PCOS patients treated for IVF. Ongoing pregnancy rates were
similar in the two protocols, although the GnRH antagonist protocol
was associated with significantly lower incidence of Grade II OHSS
(requiring monitoring on an outpatient basis but not necessitating hospitalization), as well as significantly higher proportion of women who
did not develop OHSS or developed mild hyperstimulation without
5. 687
GnRH antagonist or agonist in polycystic ovary syndrome
Table IV Logistic regression of pregnancy outcome in
patients with PCOS
Baseline parameter
Total sample
....................................
b
P-value
........................................................................................
Age (years)
20.018
0.691
2
20.055
0.039
BMI (kg/m )
Duration of infertility (years)
0.070
0.286
Number of previous attempts
20.160
0.029
FSH (IU/l)
20.034
0.694
LH (IU/l)
0.125
0.093
E2 (pg/ml)
0.001
0.887
20.256
0.438
0.218
0.526
Progesterone (ng/ml)
Type of stimulation protocol
b is the value of the coefficient and P-value shows its significance of its entrance in the
logistic regression equation. P-values in bold indicate statistical significance.
clinical relevance and did not require monitoring (Grade I). In addition,
duration of stimulation and total amount of gonadotrophin units
required were significantly lower in the antagonist compared with
the agonist protocol.
The meta-analysis by Griesinger et al. (2006) compared agonist
and antagonist protocols in a total of 305 patients with PCOS and
included four studies. In agreement with the results presented
here, pregnancy rates of 41.5 versus 37% in the agonist and in the
antagonist groups were reported. It must be noted that the
ongoing pregnancy rates reported in the present manuscript (50.9
versus 47.3% for agonists and antagonists, respectively) are higher
than the baseline pregnancy rate (35%) used for the power calculation. Higher pregnancy rates have also been shown in previous
studies in patients with PCOS [57 versus 61% (Kurzawa et al.,
2008); 58.5 versus 57.6% (Bahceci et al., 2005) for agonists and
antagonists, respectively].
It should be noted that the difference observed here in ongoing
pregnancy rates between the groups (3.6%) is below that arbitrarily
accepted as clinically significant (5%), and is not statistically significant.
However, the 95% CI shows that the current study (although, to the
best of our knowledge, the largest performed in patients with PCOS
comparing the two GnRH analogues) cannot exclude a difference of
29.6 or þ16.8%, which is clinically important. Thus it is likely that
to reject or accept the hypothesis that in PCOS patients the probability of ongoing pregnancy is independent of the analogue used, a
meta-analysis of adequate size is necessary.
In the current study it was shown that the flexible GnRH antagonist
protocol was associated with a significantly lower probability of Grade
II OHSS (requiring monitoring on an outpatient basis but not necessitating hospitalization) compared with the GnRH agonist protocol. Our
results corroborate findings from previous studies in the general population (Kolibianakis et al., 2006; Aboulghar et al., 2007; Lainas et al.
2007), which suggested that the use of GnRH antagonists was associated with a lower probability of OHSS as compared with the use of
GnRH agonists. These observations suggest that use of GnRH antagonists in the treatment of patients with PCOS results in a safer way of
performing ovarian stimulation for IVF.
It is not, however, clear what is the basis of the different occurrence
of OHSS observed between the two groups: this does not appear to
be associated with the number of COCs retrieved (Table II).
However, a significantly lower total dose of gonadotrophins was
required and a shorter duration of stimulation was necessary in the
antagonist, as compared with the agonist, group. Despite the similar
number of COCs retrieved in the two groups, it cannot be excluded
that the number of small follicles, which did not yield COCs but contributed to OHSS occurrence, might be associated with the total rFSH
dose administered and/or the duration of stimulation.
The findings of a decreased total dose of rFSH, of shorter duration
of gonadotrophin stimulation and of lower E2 levels on the day of hCG
administration in the antagonist group, should be read with caution as
this study was not double blind. Nevertheless, these results are in
agreement with those previously published by other groups
(Hohmann et al., 2003; Hwang et al., 2004; Bahceci et al., 2005;
Ragni et al., 2005; Griesinger et al., 2006; Kolibianakis et al., 2007a;
Lainas et al., 2007; Kurzawa et al. 2008).
Increased BMI was shown to have a negative effect on ongoing pregnancy rates, as calculated by logistic regression. This finding is in agreement with previous studies that reported lower pregnancy rates in
women with high BMI who had been treated with either agonist
(Orvieto et al., 2009) or antagonist protocols (Kolibianakis et al.,
2003).
It should also be noted that the dose of hCG used for triggering final
oocyte maturation in the current study was 5000 IU. This choice was
made in order to reduce the occurrence of OHSS in this high-risk
population. Consequently, regarding OHSS occurrence the conclusions drawn in the current study might not be applicable in patients
with PCOS in whom 10 000 IU hCG are used for triggering final
oocyte maturation.
Despite the lack of adequate power that would allow solid conclusions to be drawn, this is the largest study to date comparing
GnRH analogues in patients with PCOS. The flexible GnRH antagonist
protocol, as compared with the long agonist protocol, appears to offer
Table V OHSS occurrence in the GnRH agonist and antagonist groups
OHSS % (n)
Agonist group (n 5 110)
Antagonist group (n 5 110)
Difference (95% CI)
P-value (chi-square)
.............................................................................................................................................................................................
I
34.5 (38)
55.5 (61)
221.0 (233.8 to 28.1)
II
60.0 (66)
40.0 (44)
20.0 (þ7.1 to þ32.9)
III
5.5 (6)
4.5 (5)
1.0 (29.2 to þ11.2)
0.006
I, none or mild OHSS; II, moderate and severe OHSS treated at an outpatient level; III, critical OHSS requiring patient hospitalization. P-values in bold indicate statistical significance.
6. 688
similar ongoing pregnancy rates, and is associated with a significantly
lower incidence of Grade II OHSS, requiring lower gonadotrophin
amounts and a shorter duration of stimulation. Considering, in
addition, that the antagonist protocol is more patient friendly as compared with the agonist, GnRH antagonists might be the protocol of
choice for patients with PCOS. This, however, remains to be verified
by a future meta-analysis.
Supplementary data
Supplementary data are available at http://humrep.oxfordjournals.
org/.
Acknowledgements
The authors wish to thank Mr G. Iliadis for embryology work, Mrs
G. Stavropoulou for patient coordination and Mrs R. Carousou for
secretarial support during manuscript preparation.
References
Aboulghar MA, Mansour RT, Amin YM, Al-Inany HG, Aboulghar MM,
Serour GI. A prospective randomized study comparing coasting with
GnRH antagonist administration in patients at risk for severe OHSS.
Reprod Biomed Online 2007;15:271 – 279.
Bahceci M, Ulug U, Ben-Shlomo I, Erden HF, Akman MA. Use of a GnRH
antagonist in controlled ovarian hyperstimulation for assisted conception
in women with polycystic ovary disease: a randomized, prospective,
pilot study. J Reprod Med 2005;50:84 – 90.
Barash A, Weissman A, Manor M, Milman D, Ben-Arie A, Shoham Z.
Prospective evaluation of endometrial thickness as a predictor of
pituitary down-regulation after gonadotropin-releasing hormone
analogue administration in an in vitro fertilization program. Fertil Steril
1998;69:496 – 499.
Delvigne A, Demoulin A, Smitz J, Donnez J, Koninckx P, Dhont M,
Englert Y, Delbeke L, Darcis L, Gordts S et al. The ovarian
hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentric
study. I. Clinical and biological features. Hum Reprod 1993;8:
1353 – 1360.
Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN.
Prevalence and predictors of the metabolic syndrome in women
with polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:
48 – 53.
Golan A, Ron-el R, Herman A, Soffer Y, Weinraub Z, Caspi E. Ovarian
hyperstimulation syndrome: an update review. Obstet Gynecol Surv
1989;44:430 – 440.
Griesinger G, Diedrich K, Tarlatzis BC, Kolibianakis EM. GnRH-antagonists
in ovarian stimulation for IVF in patients with poor response to
gonadotrophins, polycystic ovary syndrome, and risk of ovarian
hyperstimulation: a meta-analysis. Reprod Biomed Online 2006;
13:628 – 638.
Heijnen EM, Eijkemans MJ, Hughes EG, Laven JS, Macklon NS, Fauser BC.
A meta-analysis of outcomes of conventional IVF in women with
polycystic ovary syndrome. Hum Reprod Update 2006;
12:13 – 21.
Hohmann FP, Macklon NS, Fauser BC. A randomized comparison of two
ovarian stimulation protocols with gonadotropin-releasing hormone
(GnRH) antagonist cotreatment for in vitro fertilization commencing
recombinant follicle-stimulating hormone on cycle day 2 or 5 with the
Lainas et al.
standard long GnRH agonist protocol. J Clin Endocrinol Metab 2003;
88:166 – 173.
Hwang JL, Seow KM, Lin YH, Huang LW, Hsieh BC, Tsai YL, Wu GJ,
Huang SC, Chen CY, Chen PH et al. Ovarian stimulation by
concomitant administration of cetrorelix acetate and HMG following
Diane-35 pre-treatment for patients with polycystic ovary
syndrome: a prospective randomized study. Hum Reprod 2004;19:
1993 – 2000.
Kolibianakis E, Zikopoulos K, Albano C, Camus M, Tournaye H, Van
Steirteghem A, Devroey P. Reproductive outcome of polycystic
ovarian syndrome patients treated with GnRH antagonists and
recombinant FSH for IVF/ICSI. Reprod Biomed Online 2003;7:
313 – 318.
Kolibianakis E, Albano C, Zikopoulos K, Kahn JA, Van Steirteghem A,
Devroey P. GnRH antagonists in poor responders. Acta Obstet Gynecol
Scand 2004;83:1216 – 1217.
Kolibianakis EM, Collins J, Tarlatzis BC, Devroey P, Diedrich K,
Griesinger G. Among patients treated for IVF with gonadotrophins
and GnRH analogues, is the probability of live birth dependent on the
type of analogue used? A systematic review and meta-analysis. Hum
Reprod Update 2006;12:651 – 671.
Kolibianakis EM, Kalogeropoulou L, Griesinger G, Papanikolaou EG,
Papadimas J, Bontis J, Tarlatzis BC. Among patients treated with FSH
and GnRH analogues for in vitro fertilization, is the addition of
recombinant LH associated with the probability of live birth? A
systematic review and meta-analysis. Hum Reprod Update 2007a;
13:445 – 452.
Kolibianakis EM, Papanikolaou EG, Tournaye H, Camus M, Van
Steirteghem AC, Devroey P. Triggering final oocyte maturation using
different doses of human chorionic gonadotropin: a randomized pilot
study in patients with polycystic ovary syndrome treated with
gonadotropin-releasing hormone antagonists and recombinant
follicle-stimulating hormone. Fertil Steril 2007b;88:1382– 1388.
Kurzawa R, Ciepiela P, Baczkowski T, Safranow K, Brelik P. Comparison of
embryological and clinical outcome in GnRH antagonist vs. GnRH
agonist protocols for in vitro fertilization in PCOS non-obese patients.
A prospective randomized study. J Assist Reprod Genet 2008;
25:365 – 374.
Lainas T, Zorzovilis J, Petsas G, Stavropoulou G, Cazlaris H, Daskalaki V,
Lainas G, Alexopoulou E. In a flexible antagonist protocol, earlier,
criteria-based initiation of GnRH antagonist is associated with
increased pregnancy rates in IVF. Hum Reprod 2005;20:2426– 2433.
Lainas TG, Petsas GK, Zorzovilis IZ, Iliadis GS, Lainas GT, Cazlaris HE,
Kolibianakis EM. Initiation of GnRH antagonist on Day 1 of stimulation
as compared to the long agonist protocol in PCOS patients. A
randomized controlled trial: effect on hormonal levels and follicular
development. Hum Reprod 2007;22:1540 – 1546.
Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in
novel reproductive technologies: prevention and treatment. Fertil Steril
1992;58:249 – 261.
Orvieto R, Nahum R, Meltcer S, Homburg R, Rabinson J, Anteby EY,
Ashkenazi. Ovarian stimulation in polycystic ovary syndrome patients:
the role of body mass index. Reprod Biomed Online 2009;18:
333 – 336.
Ragni G, Vegetti W, Riccaboni A, Engl B, Brigante C, Crosignani PG.
Comparison of GnRH agonists and antagonists in assisted
reproduction cycles of patients at high risk of ovarian hyperstimulation
syndrome. Hum Reprod 2005;20:2421– 2425.
Rizk B, Aboulghar MA. Classification, pathophysiology and management of
ovarian hyperstimulation syndrome. In Brinsden P (ed). In-Vitro
Fertilization and Assisted Reproduction. New York, London: The
Parthenon Publishing Group, 1999, 131 – 155.
7. GnRH antagonist or agonist in polycystic ovary syndrome
The Practice Committee of the American Society for Reproductive
Medicine. Ovarian hyperstimulation syndrome. Fertil Steril 2004;82:81–86.
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop
group. Revised 2003 consensus on diagnostic criteria and long-term
health risks related to polycystic ovary syndrome (PCOS). Hum
Reprod 2004;19:41– 47.
689
The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop
Group. Consensus on infertility treatment related to polycystic ovary
syndrome. Fertil Steril 2008;89:505 – 522.
Submitted on May 1, 2009; resubmitted on November 6, 2009; accepted on
November 16, 2009